Carregant...
PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma
Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer. Until recently, no durable treatment options were available for patients with advanced disease. As an immunogenic cancer, MCC was hypothesized to be a candidate for PD-L1/PD-1 targeted therapy. On March 23, 2017 the US...
Guardat en:
| Publicat a: | Cancer Biol Ther |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5718819/ https://ncbi.nlm.nih.gov/pubmed/29172995 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2017.1394552 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|